Filing Details
- Accession Number:
- 0001209191-19-006634
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-02-01 20:27:34
- Reporting Period:
- 2019-02-01
- Accepted Time:
- 2019-02-01 20:27:34
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 873303 | Sarepta Therapeutics Inc. | SRPT | Pharmaceutical Preparations (2834) | 930797222 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1685994 | Alexander Cumbo | 215 First Street Suite 415 Cambridge MA 02142 | Svp, Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-02-01 | 2,250 | $13.90 | 25,016 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-02-01 | 5,250 | $26.24 | 30,266 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-02-01 | 15,000 | $140.00 | 15,266 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2019-02-01 | 2,250 | $0.00 | 2,250 | $13.90 |
| Common Stock | Stock Option (right to buy) | Disposition | 2019-02-01 | 5,250 | $0.00 | 5,250 | $26.24 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2016-02-27 | 2025-02-27 | No | 4 | M | Direct |
| 46,965 | 2014-01-02 | 2023-01-02 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.
Billionaire Hedge Funds
